Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstra...

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...

The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods wherein a transoral dosage form may comprise: (1) about 5 to ab...

There is provided pharmaceutical compositions for the treatment of pain e.g. breakthrough pain which compositions comprise a mixture comprising: (a) microparticles of sufentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles

Compositions systems and methods for administration of small volume sufentanil drug dosage forms via the oral transmucosal route of a subject for treatment of pain.

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...